Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A phase 2 study of Apristor in combination with Fulvestrant in 2L therapy in advanced breast cancer patients

Trial Profile

A phase 2 study of Apristor in combination with Fulvestrant in 2L therapy in advanced breast cancer patients

Planning
Phase of Trial: Phase II

Latest Information Update: 28 Aug 2018

At a glance

  • Drugs Onapristone (Primary) ; Fulvestrant
  • Indications Advanced breast cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 28 Aug 2018 New trial record
    • 08 Aug 2018 According to a Context Therapeutics media release, this study is planned to start in early 2019
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top